ALX Oncology Holdings Inc.
ALXO
Key stats
- Open
- 1.12
- Day high
- 1.14
- Day low
- 1.00
- Previous close
- 1.12
- Volume
- 1.53M
- VWAP
- 1.06
- 52-week high
- 2.66
- 52-week low
- 0.86
- Market cap
- 154.87M
- Shares out
- 138.28M
- Employees
- 48
- Listed
- 2020
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
PHARMACEUTICAL PREPARATIONS · SOUTH SAN FRANCISCO, CA · alxoncology.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 3.0K
- Put open interest
- 53
- Put/call
- 0.02
- At-the-money IV
- 666.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 0.50 call | 0.55 | Nov 12, 3:55 PM | 184 | 2.4K | — |
| 2 put | 0.65 | Nov 2, 2:55 PM | 50 | 50 | 453.6% |
| 1.50 call | 0.15 | Oct 26, 9:38 AM | 12 | 14 | 534.0% |
| 2 call | 0.07 | Nov 5, 1:24 PM | 10 | 23 | 859.8% |
| 1 call | 0.31 | Nov 9, 3:36 PM | 7 | 608 | 666.6% |
| 0.50 put | 0.01 | Oct 22, 1:09 PM | 1 | 1 | — |
Quarterly results
Massive · Aug 6, 2026| Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | Q3 2025 to Sep 30, 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Operating income | −$18.03M | −$18.97M | −$23.02M | −$22.53M |
| Net income | −$17.97M | −$17.93M | −$22.85M | −$22.14M |
| Diluted EPS | -0.13 | -0.17 | -0.42 | -0.41 |
| Operating cash flow | −$16.06M | −$18.65M | −$18.98M | −$17.09M |
| Assets | $160.82M | $178.33M | $59.05M | $82.72M |
| Liabilities | $24.63M | $26.98M | $33.06M | $37.92M |
| Equity | $136.19M | $151.35M | $25.98M | $44.80M |
Technicals
Massive · Nov 12, 2026- 50-day average1.37
- 200-day average1.82
- RSI (14 days)42.4
Short interest
Massive · Oct 30, 2026- Oct 30, 20266.17M shares · 4.4 days to cover
- Oct 15, 20265.98M shares · 3.6 days to cover
- Sep 30, 20265.67M shares · 3.8 days to cover
- Sep 15, 20266.27M shares · 7.8 days to cover
News coverage
No stories about ALX Oncology Holdings Inc. right now.